Zollinger-Ellison Syndrome: Clinical Presentation in 261 Patients

Abstract

We prospectively evaluated the initial presenting symptoms in 261 patients with Zollinger-Ellison syndrome (ZES) over a 25-year period. Twenty-two percent of the patients had multiple endocrine neoplasia-type 1 (MEN-1) with ZES. Mean age at onset was 41.1 +/- 0.7 years, with MEN-1 patients presenting at a younger age than those with sporadic ZES (p < 0.0001). Three percent of the patients had onset of the disease < age 20 years, and 7% > 60 years. A mean delay to diagnosis of 5.2 +/- 0.4 years occurred in all patients. A shorter duration of symptoms was noted in female patients and in patients with liver metastases. Abdominal pain and diarrhea were the most common symptoms, present in 75% and 73% of patients, respectively. Heartburn and weight loss, which were uncommonly reported in early series, were present in 44% and 17% of patients, respectively. Gastrointestinal bleeding was the initial presentation in a quarter of the patients. Patients rarely presented with only 1 symptom (11%); pain and diarrhea was the most frequent combination, occurring in 55% of patients. An important presenting sign that should suggest ZES is prominent gastric body folds, which were noted on endoscopy in 94% of patients; however, esophageal stricture and duodenal or pyloric scarring, reported in numerous case reports, were noted in only 4%-10%. Patients with MEN-1 presented less frequently with pain and bleeding and more frequently with nephrolithiasis. Comparing the clinical presentation before the introduction of histamine H2-receptor antagonists (pre-1980, n = 36), after the introduction of histamine H2-receptor antagonists (1981-1989, n = 118), and after the introduction of proton pump inhibitors (PPIs) (> 1990, n = 106) demonstrates no change in age of onset; delay in diagnosis; frequency of pain, diarrhea, weight loss; or frequency of complications of severe peptic disease (bleeding, perforations, esophageal strictures, pyloric scarring). Since the introduction of histamine H2-receptor antagonists, fewer patients had a previous history of gastric acid-reducing surgery or total gastrectomy. Only 1 patient evaluated after 1980 had a total gastrectomy, and this was done in 1977. The location of the primary tumor in general had a minimal effect on the clinical presentation, causing no effect on the age at presentation, delay in diagnosis, frequency of nephrolithiasis, or severity of disease (strictures, perforations, peptic ulcers, pyloric scarring). Disease extent had a minimal effect on symptoms, with only bleeding being more frequent in patients with localized disease. Patients with advanced disease presented at a later age and with a shorter disease history (p = 0.001), were less likely to have MEN-1 (p = 0.0087), and tended to have diarrhea more frequently (p = 0.079). A correct diagnosis of ZES was made by the referring physician initially in only 3% of the patients. The most common misdiagnosis made were idiopathic peptic ulcer disease (71%), idiopathic gastroesophageal reflux disease (GERD) (7%), and chronic idiopathic diar...

Neuroendocrine tumors of the small bowels are on the rise: Early aspects and management

“…However, a review of seven series demonstrates 10% ± 3% of duodenal NET patients develop the Zollinger-Ellison syndrome (ZES), 4% ± 2% Cushing's syndrome and rare cases develop acromegaly due to a growth hormone factor releasing NET (GRFoma) and rare patients have a functional duodenal NET that is an insulinoma or a glucagonoma [7] . Patients with Zollinger-Ellison syndrome present with heartburn, gastroduodenal ulcer disease and/or chronic diarrhea [9,31] . In contrast, most ileal NETs present with symptoms either due to the ileal carcinoid itself or secondary to the development of carcinoid syndrome [13,14,32] .…”

Sporadic duodenal macrogastrinoma: a rare case report

“…There was a long delay (6 years) in diagnosis in this case as well as reported in larger studies (5-7 years) (2). The clinical presentation is not specific for gastrinoma and there is overlap of symptoms associated with this illness and other more common gastrointestinal conditions (Table) (8). Similar to almost all series of ZES patients, pain was the most promi- nent feature and diarrhea, heartburn were also pronounced symptoms in this case (2,8).…”

“…The clinical presentation is not specific for gastrinoma and there is overlap of symptoms associated with this illness and other more common gastrointestinal conditions (Table) (8). Similar to almost all series of ZES patients, pain was the most promi- nent feature and diarrhea, heartburn were also pronounced symptoms in this case (2,8). 70-90% of the patients develop peptic ulcers (2, 3), however, endoscopy did not reveal ulcers in our patient and he had not been taking antacids.…”

“…Gastrinomas can be sporadic or associated with multiple endocrine neoplasia type 1 (MEN 1) (7)(8)(9). 70% of sporadic gastrinomas form in the duodenum.…”

The role of somatostatin analogues in the treatment of neuroendocrine tumours

“…The non-functioning tumours constitute the largest group, representing approximately 50% of the endocrine pancreatic tumours (Evans et al, 1993); following in incidence are the insulinomas (25%) (de Herder et al, 2006b) and gastrinomas (15%) (Roy et al, 2000), while the remaining 15%…”